Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 17/20 | 0.43 |
| ▸ | HRH1 | P35367 | 15/20 | 0.43 |
| ▸ | HTR2B | P41595 | 15/20 | 0.43 |
| ▸ | HTR2C | P28335 | 13/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23023989 | 1.00 | HTR2A (0.43) | HTR2AHRH1HTR2BHTR2CLMNA | |
| SCHEMBL29891053 | 0.81 | CHRM2 (0.43) | HTR2AHRH1HTR2BHTR2CSIGMAR1 | |
| SCHEMBL31288595 | 0.81 | CHRM2 (0.43) | HTR2AHRH1HTR2BHTR2CSIGMAR1 | |
| SCHEMBL22493807 | 0.81 | CHRM2 (0.43) | HTR2AHRH1HTR2BHTR2CSIGMAR1 | |
| SCHEMBL21856028 | 0.75 | LMNA (0.44) | HTR2AHTR2BHTR2CLMNAHTT | |
| SCHEMBL22493731 | 0.75 | GPR3 (0.36) | HTR2AHRH1HTR2BHTR2C | |
| SCHEMBL22493728 | 0.75 | GPR3 (0.36) | HTR2AHRH1HTR2BHTR2C | |
| SCHEMBL22493727 | 0.75 | GPR3 (0.36) | HTR2AHRH1HTR2BHTR2C | |
| SCHEMBL8312002 | 0.72 | SIGMAR1 (0.50) | HTR2AHTR2BHTR2CLMNAHTT | |
| SCHEMBL23024229 | 0.71 | DRD2 (0.37) | HTR2AHRH1HTR2BHTR2CSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234958-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | D. E. SHAW RESEARCH, LLC | 2023-07-27 | — | — | US | disclosed |
| US-20220340576-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
| US-20220315586-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | SCHRODINGER, INC. | 2022-10-06 | — | — | US | disclosed |
| US-10934302-B1 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340576-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPRCAP, PTPN22, PTPN1 | HTR2A 4480/4885HRH1 4368/4885HTR2B 4584/4885 |
| US-20230234958-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPRCAP, PTPN22, PTPN1 | HTR2A 4480/4885HRH1 4368/4885HTR2B 4584/4885 |
| US-10934302-B1 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPRJ, PTPRC | HTR2A 4287/4885HRH1 4309/4885HTR2B 4635/4885 |
| US-20220315586-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPRCAP, PTPN22, PTPN1 | HTR2A 4480/4885HRH1 4368/4885HTR2B 4584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.